US niche generics player Teligent has brought in investment bank SVB Leerink to assist with “a strategic review of assets non-core to the company’s long-term strategy.” The company, which to date had built its position in the market largely with topical formulations, intends to use any proceeds from asset sales to “to improve liquidity, optimize the capital structure, and fund efforts to unlock the full potential of its newly constructed sterile-injectable manufacturing facility in Buena, New Jersey.”
“In response to inbound interest and evolving market conditions both in the US and Canada,” the New Jersey-based company commented,...




